Trick or Trade- Prohost Biotech - Exclusive Biotech Research

Category: Trick or Trade

An Evaluation of Biotech Firms Part 1

A Comprehensive Essay Part 1 Yes, we have stories to tell about some of our picked stocks which proved to be highly successful after being condemned by erroneous evaluations from unfair analysts. Some of these firms faced problems that are...

January 9, 2020

An Evaluation of Biotech Firms Part 2

A Comprehensive Essay Part 2 In Part 1 of our comprehensive essay series Vertex Pharmaceuticals ( VRTX ) was the first firm we used to make a case in point to demonstrate successful criteria and strategies towards evaluating biotech firms....

January 14, 2020

An Evaluation of Biotech Firms Part 3

A Comprehensive Essay Part 3 In parts 1 and 2 of this comprehensive essay Vertex ( VRTX ) was the firm we used as a case in point to demonstrate successful criteria and strategies towards evaluating biotech firms. As a...

January 23, 2020

The Reasons for the Immunome, Inc Stock Rally

Immunome, Inc. Immunome, Inc ( IMNM ) announced today that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 (the virus that causes COVID-19) variants, including the South African Variant ( B.1.351 ), in pseudovirus testing. This...

February 18, 2021

Why Moderna Therapeutics' Stock Is Down Today

Moderna Therapeutics’ Stock Price Soared, Then Gave Back Its Gains in Two Consecutive Days To begin with, most, if not all, development-stage firms are yo-yo games played by day traders and investors whose strategies are buying low and selling high....

February 11, 2020

It’s All About Common Sense: Intellia Therapeutics

The Nonsensical Downgrading of Development-Stage Firms Like Intellia Therapeutics It makes no sense to downgrade a development-stage firm such as CRiSPR gene editing IntelliaTherapeutics ( NTLA ) when only based on stopping short of attaining analysts’ expectations with regard to...

March 9, 2021

The FDA Approval of Biogen's Alzheimer's Disease Drug and How Cassava Sciences Alzheimer's Disease Drug Differs

Biogen Product Adulelm Approved for Alzheimer's Disease The latest news regarding Alzheimer’s disease is that of the FDA’s approval of Biogen Inc's ( BIIB ) Alzheimer disease product Adulelm (aducanumab). Although the approval seemed to be great news for Biogen...

June 12, 2021

Encouraging News from Hoth Therapeutics and Kintor Pharmaceutical Ltd About Treating Acne and Alopecia

Hoth Therapeutics Hoth Therapeutics ( HOTH ) announced that its product, HT-003, has yielded positive results in an in vivo acne therapeutic model. The model showed that HT-003 reduces the expression of toll-like receptor 2 ( TLR2 ), which happens...

July 14, 2021

An Evaluation of Biotech Firms Part 4

A Comprehensive Essay Part 4 Our fair evaluation approaches of biotechnology and biopharma companies differ depending on the sizes and statuses of the firms. We reiterate our conviction that causing a selloff of development stage biotech stocks at every announcement...

April 13, 2020

The U.S. FDA Accepts Exelixis sNDA of CABOMETYX® for Priority Review

Exelixis sNDA Accepted by the US FDA for CABOMETYX ® The U.S. Food and Drug Administration ( FDA ) accepted Exelixis ( EXEL ) supplemental New Drug Application ( sNDA ) for CABOMETYX ® (cabozantinib) as a treatment for patients...

August 6, 2021

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024